
Ovarian cancer drug approved for NHS use will prolong lives
Mirvetuximab soravtansine (also known as Elahere) is the first new drug to be approved for hard-to-treat ovarian cancer in over 20 years.
Independent Analysis and Reportage
Browse recent publishing across the configured Public content sources.

Mirvetuximab soravtansine (also known as Elahere) is the first new drug to be approved for hard-to-treat ovarian cancer in over 20 years.

Forests benefit everyone – but farmers carry the risk.

A linguistic expert explains the techniques Enron traders used to build and retain trust in their criminal strategies.

The Schiaparelli haute-couture brand continues to capitalise on its founder’s erstwhile connections to the artworld and understanding of the cultural zeitgeist

The World Cup is selling football as inclusive and diverse. It’s not so for the African players migrating to play overseas.

Iran’s team faces a hostile reception from the US government and some of its brethren in the diaspora. Yet others hope the event will trump politics — for now.

In the great expanse of oceans, a number of small, remote islands are having their moment in the spotlight. From the Chagos islands to the South China Sea, a string of islands have been thrust suddenly onto the frontline of geopolitics. Now a long-simmering tussle over two rocky islands is creating tension in the South

The treatment is shorter and more convenient, but it will not suit every man with prostate cancer.

Supergirl has long struggled to emerge from the shadow of her cousin, Superman.

Listen to football historian John Sloop trace the history of soccer in the US on The Conversation Weekly podcast.

Centuries-old conditioning techniques are remaking bone, muscle and skin at a cellular level. Modern science is only just catching up.

The Albanese government latest budget has given fodder to those seeking to feed the disillusionment that is overtaking a growing number of Australians.